Rhumbline Advisers Eiger Bio Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.28 - $0.93 $719 - $2,388	-2,568 Reduced 52.54%	2,320 $0
Q2 2023 Aug 08, 2023	SELL	$0.55 - $1.26 $27,823 - $63,742	-50,589 Reduced 91.19%	4,888 $3,000
Q1 2023 May 11, 2023	BUY	$0.89 - $2.52 $1,323 - $3,747	1,487 Added 2.75%	55,477 $50,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $7.48 $384 - $2,819	-377 Reduced 0.69%	53,990 $64,000
Q3 2022 Nov 10, 2022	BUY	$6.04 - $9.66 $20,215 - $32,332	3,347 Added 6.56%	54,367 $409,000

Q2 2022 Aug 11, 2022	BUY	$4.99 - $8.96 $64,321 - $115,494	12,890 Added 33.81%	51,020 $321,000
Q1 2022 May 12, 2022	SELL	$3.84 - $9.74 $2,976 - $7,548	-775 Reduced 1.99%	38,130 $316,000
Q4 2021 Feb 10, 2022	SELL	$5.12 - $8.19 $3,251 - $5,200	-635 Reduced 1.61%	38,905 $202,000
Q3 2021 Nov 12, 2021	BUY	$6.68 - $9.1 $7,207 - $9,818	1,079 Added 2.81%	39,540 $264,000
Q2 2021 Aug 05, 2021	BUY	$7.82 - $9.23 $93,636 - $110,520	11,974 Added 45.21%	38,461 $328,000
Q1 2021 May 06, 2021	SELL	$8.44 - $12.66 $13,335 - $20,002	-1,580 Reduced 5.63%	26,487 $234,000
Q4 2020 Feb 10, 2021	BUY	$7.98 - $12.29 $27,371 - $42,154	3,430 Added 13.92%	28,067 $345,000
Q3 2020 Nov 12, 2020	SELL	$7.96 - $12.42 $22,288 - $34,776	-2,800 Reduced 10.21%	24,637 $201,000
Q2 2020 Aug 13, 2020	BUY	$5.4 - $13.37 $28,166 - $69,737	5,216 Added 23.47%	27,437 $263,000
Q1 2020 May 06, 2020	SELL	$4.91 - $14.7 $2,837 - $8,496	-578 Reduced 2.54%	22,221 $151,000
Q4 2019 Feb 05, 2020	BUY	$9.77 - $15.66 $12,144 - $19,465	1,243 Added 5.77%	22,799 $340,000
Q3 2019 Oct 23, 2019	BUY	$9.59 - $12.0 $4,977 - $6,228	519 Added 2.47%	21,556 $221,000
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $200,692 - $314,713	21,037 New	21,037 $223,000

Others Institutions Holding EIGR

# of Institutions

Shares Held

748K

Call Options Held

Put Options Held

View Full List

About Eiger BioPharmaceuticals, Inc.

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

More about EIGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account